| 1 |
Domain-general auditory processing explains multiple dimensions of L2 acquisition in adulthood
|
|
|
|
BASE
|
|
Show details
|
|
|
| 2 |
Aptitude, experience and second language pronunciation proficiency development in classroom settings: a longitudinal study
|
|
|
|
BASE
|
|
Show details
|
|
|
| 3 |
Human DDX3 Interacts with the HIV-1 Tat Protein to Facilitate Viral mRNA Translation
|
|
|
|
BASE
|
|
Show details
|
|
|
| 6 |
Basal insulin and cardiovascular and other outcomes in dysglycemia.
|
|
|
|
In: New England Journal of Medicine, vol. 367, no. 4, pp. 319-328 (2012)
|
|
BASE
|
|
Show details
|
|
|
| 7 |
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
|
|
Bosch, J.; Gerstein, H.C.; Dagenais, G.R.; Díaz, R.; Dyal, L.; Jung, H.; Maggiono, A.P.; Probstfield, J.; Ramachandran, A.; Riddle, M.C.; Rydén, L.E.; Yusuf, S.
|
|
In: New England Journal of Medicine, vol. 367, no. 4, pp. 309-318 (2012)
|
|
Abstract:
BACKGROUND: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. METHODS: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. RESULTS: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. CONCLUSIONS: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
|
|
Keyword:
Aged; Cardiovascular Diseases/etiology; Cardiovascular Diseases/mortality; Cholesterol/blood; Combination; Diabetes Mellitus; Double-Blind Method; Drug Therapy; Fatty Acids; Female; Follow-Up Studies; Glucose Intolerance/complications; Glucose Intolerance/drug therapy; Humans; Hypoglycemic Agents/therapeutic use; Incidence; Insulin; Intention to Treat Analysis; Long-Acting/therapeutic use; Male; Middle Aged; Omega-3/therapeutic use; Proportional Hazards Models; Treatment Failure; Triglycerides/blood; Type 2/complications; Type 2/drug therapy
|
|
URL: https://doi.org/10.1056/NEJMoa1203859
https://serval.unil.ch/notice/serval:BIB_83A3987D7CC1
|
|
BASE
|
|
Hide details
|
|
|
|
|
